

# Basic Annual Drug List Updates

April 2026

TRADE NAME (generic name)	Brand/Generic	Description of Change
ANDEMBRY (garadacimab-gxii soln auto-injector 200 mg/1.2ml)	Brand	Addition, Preferred Status
DAWNZERA (donidalorsen sodium subcutaneous soln auto-inj 80 mg/0.8ml)	Brand	Addition, Preferred Status
KERENDIA (finerenone tab 40 mg)	Brand	Addition, Preferred Status
OMVOH (mirikizumab-mrkz subcutaneous sol prefill syringe 200 mg/2ml)	Brand	Addition, Preferred Status
OMVOH (mirikizumab-mrkz subcutaneous soln auto-injector 200 mg/2ml)	Brand	Addition, Preferred Status
PAZOPANIB HYDROCHLORIDE (pazopanib hcl tab 400 mg (base equiv))	Brand	Addition, Preferred Status
RASUVO (methotrexate soln pf auto-injector 10 mg/0.2ml)	Brand	Addition, Preferred Status
RASUVO (methotrexate soln pf auto-injector 12.5 mg/0.25ml)	Brand	Addition, Preferred Status
RASUVO (methotrexate soln pf auto-injector 15 mg/0.3ml)	Brand	Addition, Preferred Status
RASUVO (methotrexate soln pf auto-injector 17.5 mg/0.35ml)	Brand	Addition, Preferred Status
RASUVO (methotrexate soln pf auto-injector 20 mg/0.4ml)	Brand	Addition, Preferred Status
RASUVO (methotrexate soln pf auto-injector 22.5 mg/0.45ml)	Brand	Addition, Preferred Status
RASUVO (methotrexate soln pf auto-injector 25 mg/0.5ml)	Brand	Addition, Preferred Status
RASUVO (methotrexate soln pf auto-injector 30 mg/0.6ml)	Brand	Addition, Preferred Status
RASUVO (methotrexate soln pf auto-injector 7.5 mg/0.15ml)	Brand	Addition, Preferred Status
VRAYLAR (cariprazine hcl cap 0.5 mg (base equivalent))	Brand	Addition, Preferred Status
VRAYLAR (cariprazine hcl cap 0.75 mg (base equivalent))	Brand	Addition, Preferred Status
WEGOVY (semaglutide (weight management) tab 1.5 mg)	Brand	Addition, Preferred Status
WEGOVY (semaglutide (weight management) tab 25 mg)	Brand	Addition, Preferred Status
WEGOVY (semaglutide (weight management) tab 4 mg)	Brand	Addition, Preferred Status
WEGOVY (semaglutide (weight management) tab 9 mg)	Brand	Addition, Preferred Status
YEZTUGO (lenacapavir sodium subcutaneous soln 463.5 mg/1.5ml)	Brand	Addition, Preferred Status
YEZTUGO (lenacapavir sodium tab 300 mg)	Brand	Addition, Preferred Status
ZURNAL (nalmeferne hcl soln auto-injector 1.5 mg/0.5ml (base equiv))	Brand	Addition, Preferred Status

Blue Cross and Blue Shield of Illinois, a Division of Health Care Service Corporation, a Mutual Legal Reserve Company, an Independent Licensee of the Blue Cross and Blue Shield Association. Prime Therapeutics LLC is a separate company BCBSIL contracts with to provide pharmacy solutions. BCBSIL, as well as several independent Blue Cross and Blue Shield Plans, has an ownership interest in Prime Therapeutics.